Loading...
XSTO
XBRANE
Market cap42mUSD
Jun 11, Last price  
0.26SEK
1D
-2.59%
1Q
76.04%
Jan 2017
-99.32%
IPO
-99.19%
Name

Xbrane Biopharma AB

Chart & Performance

D1W1MN
P/E
—
P/S
2.03
EPS
—
Div Yield, %
—
Shrs. gr., 5y
73.00%
Rev. gr., 5y
219.16%
Revenues
199m
-16.77%
991,081189,523189,627433,4692,490,11720,771,000112,953,000600,0006,821,00011,533,00057,618,000238,729,000198,700,000
Net income
-266m
L-31.42%
-834,044-2,107,246-2,572,001-11,844,786-33,288,662-44,935,000-13,236,000-167,474,000-226,792,000-191,012,000-172,226,000-388,172,000-266,220,000
CFO
-134m
L-67.12%
0-2,197,432-2,668,371-12,386,674-39,426,184-36,849,00046,707,000-148,589,000-238,407,000-219,610,000-193,918,000-406,678,000-133,728,000
Earnings
Aug 26, 2025

Profile

Xbrane Biopharma AB (publ), a biotechnology company, develops, manufactures, and sells biosimilars. The company is developing Xlucane, a ranibizumab biosimilar that is in Phase III clinical trials used for the treatment of wet age-related macular degeneration, diabetic macular edema, diabetic related retinopathy, and retinal vein occlusion. Its pre-clinical phase products include Xcimzane for rheumatoid arthritis, axial spondylarthrosis, psoriatic arthritis, and psoriasis and crohn diseases; Xoncane for acute lymphocytic leukemia; Spherotide for prostate cancer, breast cancer, endometriosis, and myoma; and Xdivane for melanoma, lung, head and throat, bladder, and urinary tract cancer, as well as for renal cell carcinoma. The company has a strategic biosimilar development partnership with STADA Arzneimittel AG to evaluate development and commercialization collaborations around its Xcimzane and Xdivane preclinical biosimilars. Xbrane Biopharma AB (publ) was founded in 2008 and is headquartered in Solna, Sweden.
URL
https://xbrane.com/
IPO date
Feb 03, 2016
Employees
93
Domiciled in
SE
Incorporated in
SE

Valuation

Title
SEK in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2024‑122023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑12
Income
Revenues
198,700
-16.77%
238,729
314.33%
57,618
399.59%
Cost of revenue
371,224
549,155
247,762
Unusual Expense (Income)
NOPBT
(172,524)
(310,426)
(190,144)
NOPBT Margin
Operating Taxes
11,589
3,713
Tax Rate
NOPAT
(184,113)
(310,426)
(193,857)
Net income
(266,220)
-31.42%
(388,172)
125.39%
(172,226)
-9.83%
Dividends
Dividend yield
Proceeds from repurchase of equity
337,242
120,018
170,551
BB yield
-137.12%
-4.74%
-0.92%
Debt
Debt current
95,767
75,871
9,162
Long-term debt
138,798
211,690
67,278
Deferred revenue
Other long-term liabilities
(1,000)
8
Net debt
110,235
222,159
(121,499)
Cash flow
Cash from operating activities
(133,728)
(406,678)
(193,918)
CAPEX
(501)
(6,791)
(60,125)
Cash from investing activities
(52,246)
(16,769)
(60,125)
Cash from financing activities
243,623
298,696
148,864
FCF
(52,112)
(383,816)
(228,895)
Balance
Cash
124,330
65,402
193,994
Long term investments
3,945
Excess cash
114,395
53,466
195,058
Stockholders' equity
(1,196,722)
(1,257,195)
(869,339)
Invested Capital
1,596,978
1,660,017
1,330,262
ROIC
ROCE
EV
Common stock shares outstanding
1,529,483
253,210
225,551
Price
0.16
-98.39%
10.00
-87.82%
82.10
-21.66%
Market cap
245,941
-90.29%
2,532,096
-86.33%
18,517,704
-15.10%
EV
356,176
2,754,255
18,396,205
EBITDA
(136,571)
(288,993)
(173,568)
EV/EBITDA
Interest
35,508
2,270
2,583
Interest/NOPBT